Administration of standard non-antimetabolite chemotherapies for both Hodgkin lymphoma and non-Hodgkin lymphoma in the second and third trimester of pregnancy led to minimum incidence of maternal and fetal negative outcomes, a study from Tufts Medical Center found. At 41 months, progression-free survival and overall survival were 85% and 97%, respectively, in women with Hodgkin lymphoma, researchers reported in the Journal of Clinical Oncology.

Full Story:

Related Summaries